Taltz (Ixekizumab)
Brand Names: Taltz
Methodology & AI Transparency ⓘ
Taltz (Ixekizumab) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Taltz (Ixekizumab) represents a prescription brand-name interleukin-17a antagonist entry registered by Eli Lilly and Company with package codes 0002-7724, 0002-1445.
- 2 Real-world patient consensus: Branded interleukin-17a antagonist presentation of Ixekizumab (Eli Lilly and Company); generic reference: /meds/ixekizumab.
- 3 Typical cash cost range: Dispensing cost comparison spans $640.00 mail/discount cash up to $1696.00 uninsured retail (federal NADAC $7049.5884).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Taltz (Ixekizumab) include nausea (11.1%), nasopharyngitis (7.8%), headache (7.2%).
Ask our AI Specialists anything about Taltz (Ixekizumab)
Taltz (Ixekizumab) Mechanism, CYP450 Pathways & DailyMed Monograph
Taltz (Ixekizumab) represents a prescription brand-name interleukin-17a antagonist entry registered by Eli Lilly and Company with package codes 0002-7724, 0002-1445. Reviewed against 2026-01-22 FDA SPL standards (40 mg/.5mL Injection, Solution; 20 mg/.25mL Injection, Solution), clinical deployment addresses 1 Indications and usage taltz: ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged.
Taltz achieves therapeutic action via Ixekizumab, engaging interleukin-17a antagonist physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 40 mg/.5mL Injection, Solution; 20 mg/.25mL Injection, Solution (registered by Eli Lilly and Company, NDC 0002-7724, 0002-1445), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Taltz ($1696.00 retail) with generic Ixekizumab ($640.00 low cash).
Systemic exposure to Taltz (Ixekizumab) reflects Complete (~100%) parenteral systemic delivery for Taltz (Ixekizumab) (40 mg/.5mL Injection, Solution) absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar taltz (ixekizumab) conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 6–19 hour t½ intervals for Taltz (Ixekizumab) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after taltz (ixekizumab) administration response profile).
Dosing protocols (40 mg/.5mL Injection, Solution or 20 mg/.25mL Injection, Solution or 80 mg/mL Injection, Solution) balance efficacy (92.00% patient satisfaction across 8 logs) against nausea (11.1% of reports), nasopharyngitis (7.8% of reports), headache (7.2% of reports), with strict avoidance in contraindicated in patients with prior serious allergic response to taltz (ixekizumab) (ndc 0002-7724); severe baseline organ impairment where ixekizumab accumulation exceeds safe therapeutic margins.
Reconcile eGFR-adjusted medications before escalating Taltz (Ixekizumab) in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Taltz (Ixekizumab) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Taltz (Ixekizumab) (NDC 0002-7724)
- Severe baseline organ impairment where Ixekizumab accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (8 Reports)
Taltz (Ixekizumab) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Taltz (Ixekizumab))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Long-term real-world benefits and safety of ixekizumab: A 5-year analysis of the: What a 1,346-Participant Study Found IXE demonstrates sustained efficacy and consistent safety through 264 weeks in patients using the approved dose. Journal of the American Academy of Dermatology • 2021-08-15 • Phase III Randomized Trial | N = 1,346 | 96/100 | PMID 33253833 ↗ |
| New Insights on Clinimetric Validation of the Assessment of Spondyloarthritis International: What a 341-Participant Study Found The ASAS HI demonstrated reliability, construct validity, known groups discrimination, and responsiveness in adults with r-axSpA in 2 clinical trials. The Journal of rheumatology • 2023-06-15 • Phase III Randomized Trial | N = 341 | 93/100 | PMID 36725056 ↗ |
| Can This Approach Help? Inside the Latest Research on Improvement from ixekizumab treatment in patients with psoriatic arthritis who IXE improved the signs and symptoms of PsA in a population of difficult-to-treat patients with inadequate response to one or two TNFi. Rheumatology (Oxford, England) • 2021-09-01 • Phase III Randomized Trial | N = 123 | 88/100 | PMID 33479721 ↗ |
| Can This Approach Help? Inside the Latest Research on Recapture and retreatment rates with ixekizumab after withdrawal of therapy in Ninety-six per cent of patients withdrawn to placebo recaptured at least ASDAS LDA and 71% recaptured ASDAS ID with IXE retreatment at week 104. Annals of the rheumatic diseases • 2023-02-15 • Phase III Randomized Trial | N = 53 | 88/100 | PMID 36100350 ↗ |
| Can This Approach Help? Inside the Latest Research on Time to Loss of Response following Withdrawal of Ixekizumab in Patients with A small subset of patients maintained high levels of disease control through Week 60. Acta dermato-venereologica • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35170742 ↗ |
Taltz (Ixekizumab) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $7049.5884/unit (~$211487.65/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Taltz (Ixekizumab) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Taltz (Ixekizumab) RxNorm Concept ID | 1745108 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $7049.5884 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Taltz (Ixekizumab) Patient Community, Cohort Filters & Dosage Logs
Deterministic Taltz (Ixekizumab) reference combining NIH RxNorm (1745108), Medicaid NADAC ($7049.5884/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Taltz (Ixekizumab) community threads and patient logs by age, biological sex, dosage, and treatment duration.